Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-04-21
DOI
10.3389/fimmu.2016.00152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15
- (2016) Rebecca B. Delconte et al. IMMUNITY
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- CD56brightCD16−NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+T Cell Proliferation
- (2015) Fabio Morandi et al. JOURNAL OF IMMUNOLOGY
- The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
- (2015) R H Rouce et al. LEUKEMIA
- Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
- (2015) Richard W. Childs et al. NATURE REVIEWS DRUG DISCOVERY
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity
- (2015) Jie Yin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
- (2015) W. Deng et al. SCIENCE
- NK cells regulating T cell responses: mechanisms and outcome
- (2015) Josh Crouse et al. TRENDS IN IMMUNOLOGY
- The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
- (2015) Cinzia Fionda et al. Oncotarget
- NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
- (2015) Wei Wang Frontiers in Immunology
- CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- (2015) Margaret K. Callahan et al. Frontiers in Oncology
- Modulation of Immune Cell Functions by the E3 Ligase Cbl-b
- (2015) Christina Lutz-Nicoladoni et al. Frontiers in Oncology
- Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells
- (2015) Elisa Lo Monaco et al. NEOPLASIA
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- Development, Differentiation, and Diversity of Innate Lymphoid Cells
- (2014) Andreas Diefenbach et al. IMMUNITY
- T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow
- (2014) Cécile Daussy et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
- (2014) Priyanka Sathe et al. Nature Communications
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
- (2014) I. Melero et al. Cancer Discovery
- Regulation and Role of EZH2 in Cancer
- (2014) Hirohito Yamaguchi et al. Cancer Research and Treatment
- Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells
- (2014) Dorothy K Sojka et al. eLife
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Reversal of natural killer cell exhaustion by TIM-3 blockade
- (2014) Anne Gallois et al. OncoImmunology
- Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy
- (2013) Yhun Yhong Sheen et al. Biomolecules & Therapeutics
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Chromatin targeting drugs in cancer and immunity
- (2013) R. Prinjha et al. GENES & DEVELOPMENT
- Natural killer cell deficiency
- (2013) Jordan S. Orange JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Natural killer cell biology: An update and future directions
- (2013) Kerry S. Campbell et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- T and NK cells: two sides of tumor immunoevasion
- (2013) Doriana Fruci et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Location and cellular stages of natural killer cell development
- (2013) Jianhua Yu et al. TRENDS IN IMMUNOLOGY
- CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
- (2013) Eva Maria Putz et al. Cell Reports
- Regulation of murine natural killer cell commitment
- (2013) Nicholas D. Huntington et al. Frontiers in Immunology
- Regulation of Mouse NK Cell Development and Function by Cytokines
- (2013) Antoine Marçais et al. Frontiers in Immunology
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
- (2012) Ariane Thielens et al. CURRENT OPINION IN IMMUNOLOGY
- Complexities of TGF-β Targeted Cancer Therapy
- (2012) Erin C. Connolly et al. International Journal of Biological Sciences
- When NK cells overcome their lack of education
- (2012) Baptiste N. Jaeger et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Natural Killer Cell Tolerance: Control by Self or Self-Control?
- (2012) B. N. Jaeger et al. Cold Spring Harbor Perspectives in Biology
- How melanoma cells inactivate NK cells
- (2012) Gabriella Pietra et al. OncoImmunology
- Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
- (2011) Dawn Holt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TGF- downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients
- (2011) C. A. Crane et al. NEURO-ONCOLOGY
- Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity
- (2011) Erica B. Wilson et al. PLoS One
- The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
- (2010) A. K. Hsu et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Activating and inhibitory receptors of natural killer cells
- (2010) Hollie J Pegram et al. IMMUNOLOGY AND CELL BIOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
- (2010) Avnish Kapoor et al. NATURE
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- In vivotumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL-2
- (2009) Gustaf Vahlne et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels
- (2009) Ulrike Lorenz IMMUNOLOGICAL REVIEWS
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
- (2008) Ron Firestein et al. NATURE
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now